Terns Pharmaceuticals, Inc. - TERN
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Mar 27, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Commodore Capital LP | 1.4% | 1,475,000 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Commodore Capital Master LP | 1.4% | 1,475,000 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Robert Egen Atkinson | 1.4% | 1,475,000 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Michael Kramarz | 1.4% | 1,475,000 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Vivo Capital Fund VIII, L.P. | 0.9% | 966,461 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Vivo Capital Surplus Fund VIII, L.P. | 0.1% | 133,415 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Vivo Capital VIII, LLC | 1.0% | 1,099,876 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Vivo Opportunity Fund Holdings, L.P. | 2.5% | 2,700,615 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Vivo Opportunity, LLC | 2.5% | 2,700,615 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Vivo Opportunity Cayman Fund, L.P. | 0.2% | 241,652 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Vivo Opportunity Cayman, LLC | 0.2% | 241,652 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Deep Track Capital, LP | 2.97% | 3,150,000 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Deep Track Biotechnology Master Fund, Ltd. | 2.97% | 3,150,000 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | David Kroin | 2.97% | 3,150,000 | View |
| Feb 12, 2026 | SCHEDULE 13G | Adage Capital Management, L.P. | 5.1% | 5,550,000 | View |
| Feb 12, 2026 | SCHEDULE 13G | Robert Atchinson | 5.1% | 5,550,000 | View |
| Feb 12, 2026 | SCHEDULE 13G | Phillip Gross | 5.1% | 5,550,000 | View |
| Feb 12, 2026 | SCHEDULE 13G/A | Soleus Capital Master Fund, L.P. | 0.2% | 212,710 | View |
| Feb 12, 2026 | SCHEDULE 13G/A | Soleus Capital, LLC | 0.2% | 212,710 | View |
| Feb 12, 2026 | SCHEDULE 13G/A | Soleus Capital Group, LLC | 0.2% | 212,710 | View |
| Feb 12, 2026 | SCHEDULE 13G/A | Soleus Capital Management, L.P. | 0.2% | 212,710 | View |
| Feb 12, 2026 | SCHEDULE 13G/A | Soleus GP, LLC | 0.2% | 212,710 | View |
| Feb 12, 2026 | SCHEDULE 13G/A | Guy Levy | 0.2% | 212,710 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Commodore Capital LP | 6.5% | 5,700,000 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Commodore Capital Master LP | 6.5% | 5,700,000 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Robert Egen Atkinson | 6.5% | 5,700,000 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Michael Kramarz | 6.5% | 5,700,000 | View |
| Nov 05, 2025 | SCHEDULE 13D/A | — | 1.0% | — | View |
| Oct 31, 2025 | SCHEDULE 13G | The Vanguard Group | 5.21% | 4,559,917 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.